entertainment -WSS

entertainment

author：fashion 2025-08-23 08:57:46 - browse：2333

Medicare generally pays far more for CAR-T drugs that are administered in outpatient departments than it does for inpatient care. Adobe

WASHINGTON — Hospitals for years have complained that Medicare pays so little for CAR-T cancer treatments that they sometimes lose money administering the incredibly expensive treatments. But that could soon change: if drug companies succeed in making the cancer treatments safer, hospitals could provide them more often in outpatient departments, where payment is higher.

CAR-T uses the body’s own immune system to kill cancerous cells. The procedure, regulated as a drug, involves taking T cells from a patient’s blood, adding chimeric antigen receptors (CAR) to the T cells that kill cancer, and injecting the CAR-T treatment back into the patient.

It’s worked wonders in many cancer patients who have run out of options. But right now it’s almost exclusively administered in hospitals, because the side effects can require aggressive treatments. In many cases, the CAR-T cells trigger immune reactions that can be life-threatening.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： NIH documents show early flaws of $1.6 billion long Covid program

focus

WSS

Intellia reports positive results for its CRISPR

Shifting the focus from loneliness to social health

With trial win, GSK could get blood cancer drug back on market

How to increase colonoscopy rates? Looks like an AI can help

HIV drugs protect against transmission, even in unprotected sex

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

leisure time

entertainment

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

Ionis drug prevents swelling attacks due to hereditary angioedema

Anesthesiologist group: stop taking Ozempic before surgery

In early work, researchers turn to CRISPR to treat Alzheimer's

Malaria cases in Florida and Texas: Here’s what you need to know

How Medicaid coverage policies for immigrants impact new moms

Moonlake's readout produced a cash windfall. Risks remain

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

As demand for Covid shots wanes, Moderna seeks its next success

Group opposing PBM reform sets lobbying record

focus

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Sanders adds drug shortage policies to pandemic preparedness bill

Intellia reports positive results for its CRISPR

ASCO: AstraZeneca says CAR

At ASCO, AstraZeneca reports strong data for breast cancer drug

With trial win, GSK could get blood cancer drug back on market

hotspot

leisure time

focus

focus